These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Barradell LB, Bryson HM. Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976 [Abstract] [Full Text] [Related]
3. Cefepime: a new fourth-generation cephalosporin. Okamoto MP, Nakahiro RK, Chin A, Bedikian A, Gill MA. Am J Hosp Pharm; 1994 Feb 15; 51(4):463-77; quiz 541-2. PubMed ID: 8017411 [Abstract] [Full Text] [Related]
4. Cefepime: a fourth-generation parenteral cephalosporin. Wynd MA, Paladino JA. Ann Pharmacother; 1996 Dec 15; 30(12):1414-24. PubMed ID: 8968455 [Abstract] [Full Text] [Related]
5. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime. Masuyoshi S, Hiraoka M, Inoue M, Tomatsu K, Hirano M, Mitsuhashi S. Drugs Exp Clin Res; 1989 Dec 15; 15(1):1-10. PubMed ID: 2663406 [Abstract] [Full Text] [Related]
9. Low-dosage cefepime as treatment for serious bacterial infections. Giamarellou H. J Antimicrob Chemother; 1993 Nov 15; 32 Suppl B():123-32. PubMed ID: 8150755 [Abstract] [Full Text] [Related]
10. Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use. Kearns GL, Young RA. Clin Pharmacokinet; 1994 Mar 15; 26(3):169-89. PubMed ID: 8194281 [Abstract] [Full Text] [Related]
11. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients. Isla A, Gascón AR, Maynar J, Arzuaga A, Toral D, Pedraz JL. Clin Ther; 2005 May 15; 27(5):599-608. PubMed ID: 15978309 [Abstract] [Full Text] [Related]
12. Cefepime as treatment for osteomyelitis and other severe bacterial infections. Jauregui L, Matzke D, Scott M, Minns P, Hageage G. J Antimicrob Chemother; 1993 Nov 15; 32 Suppl B():141-9. PubMed ID: 8150758 [Abstract] [Full Text] [Related]
13. The pharmacokinetic profile of a new generation of parenteral cephalosporin. Rybak M. Am J Med; 1996 Jun 24; 100(6A):39S-44S. PubMed ID: 8678096 [Abstract] [Full Text] [Related]
14. A non-comparative, multicentre study of cefepime in the treatment of serious bacterial infections. Mouton Y, Chidiac C, Humbert G, Leroy J, Veyssier P, Modai J, Bertrand A, Dellamonica P, Micoud M, Stahl JP. J Antimicrob Chemother; 1993 Nov 24; 32 Suppl B():133-40. PubMed ID: 8150757 [Abstract] [Full Text] [Related]
18. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN, Sader HS, Fritsche TR, Pottumarthy S. Diagn Microbiol Infect Dis; 2007 Jan 24; 57(1):109-16. PubMed ID: 16930923 [Abstract] [Full Text] [Related]
19. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Endimiani A, Perez F, Bonomo RA. Expert Rev Anti Infect Ther; 2008 Dec 24; 6(6):805-24. PubMed ID: 19053894 [Abstract] [Full Text] [Related]